STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBNX
  4. [Form 4] Beta Bionics, Inc. Insider Trading Activity

BBNX CFO exercises options, sells shares under Rule 10b5-1 plan

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Beta Bionics (BBNX) reported an insider transaction by its Chief Financial Officer on 10/01/2025. The CFO exercised employee stock options for 15,018 shares at an exercise price of $5.10 per share, then sold 14,918 shares at a weighted average price of $20.76 and an additional 100 shares at $21.08, pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025.

Following these transactions, the officer beneficially owned 44,041 shares directly. The option exercise related to an award covering 15,018 underlying shares that vests in 48 equal monthly installments measured from September 14, 2023 and carries an expiration date of September 13, 2033. After the reported activity, 74,677 derivative securities (employee stock options) were beneficially owned.

Positive

  • None.

Negative

  • None.

Insights

Routine Form 4: option exercise and planned sales under 10b5-1.

The CFO of Beta Bionics executed an option exercise for 15,018 shares at an exercise price of $5.10 on 10/01/2025, immediately followed by open-market sales of 14,918 shares at a weighted average of $20.76 and 100 shares at $21.08. The filing states these sales were made under a Rule 10b5-1 plan adopted on May 15, 2025.

Post-transaction, direct share ownership stood at 44,041, and derivative holdings were 74,677 employee stock options. The option grant vests monthly over 48 installments from September 14, 2023 and expires on September 13, 2033.

This is a standard liquidity and compensation event. Actual market impact depends on overall trading volumes and holder activity.

Insider Feider Stephen
Role Chief Financial Officer
Sold 15,018 shs ($312K)
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) 15,018 $0.00 --
Exercise Common Stock 15,018 $5.10 $77K
Sale Common Stock 14,918 $20.76 $310K
Sale Common Stock 100 $21.08 $2K
Holdings After Transaction: Employee Stock Option (right to buy) — 74,677 shares (Direct); Common Stock — 59,059 shares (Direct)
Footnotes (1)
  1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. The weighted average sale price for the transaction reported was $20.76 and the range of prices were between $20.03 and $21.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Feider Stephen
(Last) (First) (Middle)
C/O BETA BIONICS, INC.
11 HUGHES
(Street)
IRVINE CA 92618
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 M 15,018 A $5.1 59,059 D
Common Stock 10/01/2025 S(1) 14,918 D $20.76(2) 44,141 D
Common Stock 10/01/2025 S(1) 100 D $21.08 44,041 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $5.1 10/01/2025 M 15,018 (3) 09/13/2033 Common Stock 15,018 $0 74,677 D
Explanation of Responses:
1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
2. The weighted average sale price for the transaction reported was $20.76 and the range of prices were between $20.03 and $21.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
/s/ Stephen Feider 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did BBNX’s CFO report on Form 4?

An option exercise for 15,018 shares at $5.10 per share, followed by sales of 14,918 shares at a weighted average of $20.76 and 100 shares at $21.08.

Was the BBNX insider sale under a Rule 10b5-1 plan?

Yes. The filing states sales were made pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.

How many BBNX shares does the CFO own after the transactions?

Direct beneficial ownership is 44,041 shares after the reported transactions.

What options remain after the BBNX transaction?

The filing shows 74,677 derivative securities (employee stock options) beneficially owned after the transactions.

What are the vesting and expiration terms of the exercised BBNX options?

They vest in 48 equal monthly installments from September 14, 2023 and expire on September 13, 2033.

What prices were disclosed for the BBNX share sales?

A weighted average sale price of $20.76 (range $20.03–$21.03) for 14,918 shares, and $21.08 for 100 shares.